MPP应用布地奈德序贯联合阿奇霉素治疗对患儿血清IFN-γ、MCP-4水平的影响

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (527 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨布地奈德联合阿奇霉素序贯对肺炎支原体肺炎小儿血清IFN-γ、MCP-4的影响。方法采用临床对照研究方式抽取本研究132例MMP患儿,随机分为观察组与对照组,每组66例。患儿均予以常规止咳、平喘等对症治疗,对照组予以阿奇霉素序贯治疗,观察组采用阿奇霉素序贯联合布地奈德辅助治疗。比较两种治疗方式的疗效,并检测治疗前后血清IFN-γ、MCP-4水平变化。结果观察组的体温正常时间、咳嗽消失及胸片正常时间分别是（4.1±0.8）d、（6.7±2.2）d、（8.8±3.4）d,均显著低于对照组的（4.5±1.3）d、（7.8±2.7）d、（10.5±3.6）d,差异均具有统计学意义（P<0.05）;治疗后观察组的IFN-γ为（14.3±2.8）ng/L,MCP-4为（26.3±5.4）pg/mL,均显著低于对照组的（17.5±4.7）ng/L、（32.7±7.2）pg/mL,差异均具有统计学意义（P<0.05）。结论布地奈德联合阿奇霉素序贯可显著降低MMP小儿血清IFN-γ、MCP-4水平,促使患儿恢复健康。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李缓
	孟岗

关键词 ：肺炎支原体肺炎, 布地奈德, 阿奇霉素, 炎性因子

Abstract：Objective To explore the effects of sequential therapy of budesonide combined with azithromycin on levels of serum IFN-γ and MCP-4 in MMP children patients. Methods A clinically controlled study was used to collect 132 MMP children patients,and they were randomly divided into the observation group and the control group with 66 cases in each group.The children patients were all given symptomatic treatments such as regular cough relief and asthma relief,and the control group was given azithromycin sequential therapy,and the observation group was given sequential therapy of azithromycin combined with budesonide.The efficacy of the two treatment method was compared,and the changes of serum IFN-γ and MCP-4 levels were detected before and after treatment. Results The normal temperature recovery time,cough disappearance time and normal chest radiograph time were（4.1±0.8）d,（6.7±2.2）d and（8.8±3.4）d in the observation group,which were significantly lower than those in the control group with（4.5±1.3）d,（7.8±2.7）d and（10.5±3.6）d（P<0.05）.The levels of IFN-γ and MCP-4 after treatment were（14.3±2.8）ng/L and（26.3±5.4）pg/mL in the observation group,which were significantly lower than those in the control group with（17.5±4.7）ng/L and（32.7±7.2）pg/mL（P<0.05）. Conclusion Sequential therapy of budesonide combined with azithromycin can significantly reduce the levels of serum IFN-γ and MCP-4,and promote the health recovery of children patients with MMP.

Key words： Mycoplasma pneumoniae pneumonia Budesonide Azithromycin Inflammatory factors

收稿日期: 2020-06-30

PACS:

R375+.2

引用本文:

李缓, 孟岗. MPP应用布地奈德序贯联合阿奇霉素治疗对患儿血清IFN-γ、MCP-4水平的影响[J]. 哈尔滨医药, 2021, 41(6): 25-27.
Li Huan, Meng Gang. Effects of Sequential Therapy of Budesonide Combined With Azithromycin on Levels of Serum IFN-γ and MCP-4 in Children Patients With MPP. journal1, 2021, 41(6): 25-27.

链接本文:

http://www.hrbyybjb.org.cn/CN/ 或 http://www.hrbyybjb.org.cn/CN/Y2021/V41/I6/25

[1] Ha SG,Oh KJ,Ko KP,,et al.Therapeutic efficacy.Therapeutic efficacy and safety of prolonged macrolide,corticosteroid,doxycycline,and levofloxacin against macrolide-unresponsive mycoplasma pneumoniae pneumonia in children[J].J Korean Med Sci,2018,18;33(43):e268.
[2] 杨明珠,韩改琳,倪莉.布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿血清TNF-α、CRP、IL-5及VEGF的影响研究[J].陕西医学杂志,2019,48(03):113-115.
[3] 杨敏,李林瑞,孟燕妮,等.布地奈德辅助治疗小儿支气管哮喘对T淋巴细胞亚群及相关细胞因子的影响[J].疑难病杂志,2018,17(3):255-258,263.
[4] 王炳征,陈玺,毛云英.小儿难治性肺炎支原体肺炎78例临床诊治分析[J].陕西医学杂志,2017,46(5):567-568.
[5] 杨雪雯,王红坡.孟鲁司特钠联合阿奇霉素治疗小儿支原体肺炎的临床疗效[J].山西职工医学院学报,2019,29(3):7-9.
[6] 王秀琴. 小儿肺炎支原体肺炎的临床特点及诊治分析[J].山西医药杂志,2018,47(10):1195-1196.
[7] Jo DS.The best second option to treat macrolide-unresponsive mycoplasmal pneumonia in children[J].J Korean Med Sci,2018,33(43):e281.
[8] 费新,华亚军,潘伟,等.盐酸氨溴索联合阿奇霉素序贯疗法对支原体肺炎患儿细胞因子及共刺激分子的影响[J].蚌埠医学院学报,2018,43(2):185-188.
[9] 郝凤清. 布地奈德联合特布他林雾化吸入治疗毛细支气管炎疗效观察[J].中国药物与临床,2018,18(3):451-452.
[10] 李俊梅,郑成中,张曼,等.儿童难治性肺炎支原体肺炎的临床特点及血清IL-4、IL-6、IL-10、IFN-γ的变化分析[J].现代生物医学进展,2018,18(24):178-182.
[11] 于畅,张晗,尚云晓.儿童难治性肺炎支原体肺炎支气管肺泡灌洗液细胞因子检查意义及与血清C反应蛋白相关性研究[J].国际儿科学杂志,2019,46(11):845-851.